StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Mavyret (glecaprevir/pibrentasvir by Quarter

Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — International reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Mavyret (glecaprevir/pibrentasvir: -14.9% in Q2 2026, down 9.8 pts from a year earlier.

Latest, Q2 2026
-14.9%
Period ended Jun 30, 2026
Change on a year earlier
-9.8 pts
-5.1% in Q2 2025
History
30 quarters
Since Q1 2019
Sources
30
Documents cited below

Where the Q2 2026 figure comes from

“|| Mavyret | 133 | 162 | 295 | (27.7) | (14.9) | (21.2) | (16.9) | (22.2)”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMavyret (glecaprevir/pibrentasvir — Hepatitis C) — International reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-14.9%-9.8 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 20262.4%+22.8 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20254.9%+20.3 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 20256.9%+30.0 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-5.1%-8.9 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025-20.4%-26.6 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024-15.4%-12.4 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 2024-23.1%-28.3 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20243.8%+4.7 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 20246.2%+14.3 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 2023-3.0%+15.8 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 20235.2%+25.8 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-0.9%+17.1 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023-8.1%+5.8 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-18.8%-7.2 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-20.6%-26.3 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Mavyret (glecaprevir/pibrentasvir (%), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/mavyret-intl-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.